VISTAGEN

Executives
Shawn K. Singh
J.D. Chief Executive Officer and Director
H. Ralph Snodgrass Ph.D.
President and Chief Scientific Officer
Mark A. Smith M.D Ph.D.
Chief Medical Officer
Ann Cunningham MBA
Chief Commercial Officer and Director
Jerrold D. Dotson CPA
Vice President, Chief Financial Officer and Secretary
Reid Adler J.D.
Chief Legal Officer
Allen (Jo) Cato III Ph.D.
Senior Vice President, Development Operations
Ross A. Baker Ph.D. MBA
, Vice President, Global Medical Affairs
Trisha Fitzmaurice
Vice President, Human Resources
Mark J. Ginski Ph.D.
Senior Vice President, Head of CMC
Jaakko Lappalainen M.D ,Ph.D.
Senior Vice President, Global Clinical Development & Pharmacovigilance
Erik Berglund M.D. Ph.D. R.A.C.
Vice President, Global Regulatory Affairs
Mark Flather
Vice President, Investor Relations
Rita E. Hanover, Ph.D. R.A.C.
Vice President, Biostatistics and Clinical Analytics
Mark A. McPartland
Vice President of Corporate Development
Louis Monti, M.D Ph.D.
Vice President,Translational Medicine
Joshua Prince, MBA
Vice President, Strategic Insights & Analytics
Ellis Wilson Jr.M.S.E.M.B.A.
Vice President, Global Clinical Operations
Board
Jon S. Saxe, J.D, LL.M
Chairman of the Board
Ann Cunningham, MBA
Chief Commercial Officer and Director
Joanne Curley Ph.D.
Director
Mary L. Rotunno
J.D ,Director
Maggie FitzPatrick
Director
Jerry Gin
Ph.D, MBA, Director
Shawn K. Singh
J.D, Chief Executive Officer and Director
Contact
Website
www.vistagen.com
Address
343 Allerton Avenue South San Francisco, CA 94080
Twitter
twitter.com/vistagen
Facebook
www.facebook.com/VistaGen
Linkdin
www.linkedin.com/company/vistagen-therapeutics-inc-/?trk=top_nav_home

About VISTAGEN

VistaGen Therapeutics (NASDAQ: VTGN) is a clinical:stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. Our pipeline includes three clinical:stage CNS drug candidates, PH94B, PH10, and AV:101, each with a differentiated mechanism of action, an exceptional safety profile in all clinical studies to date, and therapeutic potential in multiple CNS markets.